India Globalization Capital Rises as Patent Receives THC Components To Deal with Alzheimer’s Illness – India Globalization Capital (IGC)
India Globalization Capital, Inc. (AMEX: IGC) announced Thursday that it was received a patent from the US Patent and Trademark Office for the treatment of Alzheimer’s disease. The patent (# 11,065,225) is called “Ultra-low dose THC as a potential therapeutic and prophylactic agent for Alzheimer’s disease. “
The Potomac, Maryland-based cannabis company noted the first patent application was filed in August 2016 by the University of South Florida. The following year in May, IGC has signed an exclusive patent application agreement with the university
and related research on Alzheimer’s disease.
The patent obtained relates to the proprietary formulation – IGC-AD1, which is intended to aid the treatment of patients with Alzheimer’s disease. The formulation is the subject of IGC’s Phase 1 clinical trial.
IGC recently announced the completion of its Phase 1 placebo-controlled, multiple dose escalation (MAD) study to determine the safety of IGC-AD1, which is being used THC in patients with Alzheimer’s disease.
India Globalization Capital’s shares traded 132% higher at $ 3.44 per share at the time of writing Thursday morning.
Photo: Courtesy Jeff W on Unsplash
© 2021 Benzinga.com. Benzinga does not offer investment advice. All rights reserved.